Article
Medicine, General & Internal
Yu Meng, Quan Quan, Fenfen Zhang, Yao Liu, Siling Ren, Xiaoling Mu
Summary: This study investigated the prognostic value of the Ki-67 index in endometrial stromal sarcoma and identified a cut-off value of 35% for predicting recurrence. High Ki-67 index and ovarian preservation were significantly associated with shorter progress free survival. The Ki-67 index could serve as a useful prognostic marker in endometrial stromal sarcoma.
FRONTIERS IN MEDICINE
(2022)
Review
Oncology
Matthew G. Davey, Sean O. Hynes, Michael J. Kerin, Nicola Miller, Aoife J. Lowery
Summary: In breast cancer development, the expression of Ki-67 is a valuable indicator for prognosis and treatment decision making. The advent of molecular medicine has transformed breast cancer management by recognizing the heterogeneity of the disease and using a combination of factors for substratification and personalization of treatment modalities. Routine evaluation of Ki-67 as a proliferation marker in breast cancer patients has limitations, but promising strategies are being explored to enhance its utility in future oncology.
Article
Oncology
Mingzhu Jia, Jiangchuan Pi, Juan Zou, Min Feng, Huiling Chen, Changsheng Lin, Shuqi Yang, Xue Xiao
Summary: This study determines the optimal cut-off value of Ki-67 as 33% for predicting recurrence in early low-risk endometrial cancer (EC), providing important quantitative information for defining the specific value of Ki-67 that leads to high-risk recurrence.
Article
Oncology
Guojing Zhang, Zhongyi Shi, Lina Liu, Heqing Yuan, Zheng Pan, Wenxu Li, Yu Tao, Zhaoming Huang, Xiaoying Huang, Chao Lin
Summary: This study found that the expression of p53 and Ki-67 is prognostically relevant to chemotherapy sensitivity and prognosis in patients with triple-negative breast cancer (TNBC), with higher recurrence rates in patients with positive expression.
TRANSLATIONAL CANCER RESEARCH
(2021)
Review
Oncology
Qixin Liu, Ziheng Peng, Liangfang Shen, Lin Shen
Summary: Ki-67 overexpression is associated with poor overall survival rates in melanoma patients, but not correlated with PFS and RFS rates. Ki-67 expression levels are associated with tumor thickness.
FRONTIERS IN ONCOLOGY
(2021)
Article
Obstetrics & Gynecology
Zeliha Atak, Ezgi Isil Turhan, Sakine Rahimli Ocakoglu, Ozlem Ozgun Uyaniklar
Summary: The study found that the expression of Ki-67 in endometrial polyps is related to different abnormal uterine bleeding patterns, with higher expression in the premenopausal patient group and the highest in patients with heavy menstrual bleeding. This may have predictive value for treatment response and prognosis.
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY
(2022)
Article
Oncology
Erdem Cubukcu, Ahmet Bilgehan Sahin, Fatma Oz Atalay, Birol Ocak, Mine Ozsen, Candan Demiroz Abakay, Kemal Ozerkan, Ulviyya Hasanzade, Merve Mesahorli, Adem Deligonul, Hakan Ozan, Turkkan Evrense
Summary: The study investigated prognostic factors in low-risk endometrial cancer by analyzing clinical, histopathological, and laboratory parameters. The results showed that lower levels of Ki-67 index and NLR were associated with longer recurrence-free survival, highlighting their prognostic implications in low-risk EC.
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Li Zhang, Mengyi Shen, Dingyi Zhang, Xin He, Qinglin Du, Nian Liu, Xiaohua Huang
Summary: A nomogram based on dual-sequence MRI radiomic features and clinical characteristics was developed to assess Ki-67 expression in breast cancer. It showed improved prediction efficiency compared to single-sequence models and clinical models.
JOURNAL OF MAGNETIC RESONANCE IMAGING
(2023)
Article
Multidisciplinary Sciences
Bulat Zagidullin, Annukka Pasanen, Mikko Loukovaara, Ralf Butzow, Jing Tang
Summary: This study applies Cox proportional hazards and optimal survival tree algorithms to predict the survival of endometrial carcinoma patients, demonstrating the advantages of different models in risk assessment. The study also explores new research hypotheses using visual interpretable tree models and identifies important risk factors.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Shintaro Sugita, Keiko Segawa, Noriaki Kikuchi, Tomoko Takenami, Tomomi Kido, Makoto Emori, Yukinori Akiyama, Kohichi Takada, Shiro Hinotsu, Tadashi Hasegawa
Summary: This study examined the prognostic usefulness of a modified version of the Demicco risk models that includes the Ki-67 labeling index. The results showed that the modified risk models were effective for predicting the prognosis in patients with solitary fibrous tumor (SFT).
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2022)
Article
Oncology
Zhihua Li, Fang Li, Cheng Pan, Zhicheng He, Xianglong Pan, Quan Zhu, Weibing Wu, Liang Chen
Summary: Ki-67 expression varied significantly across histological subtypes of LUAD, with solid-predominant adenocarcinoma (SPA) showing the highest expression level. Ki-67 expression level and tumor size contributed to the survival differences between LUAD histological subtypes.
Review
Cell Biology
Nuria Andres-Sanchez, Daniel Fisher, Liliana Krasinska
Summary: Ki-67 is a cell proliferation biomarker widely used in histopathology. Although its expression and localization throughout the cell cycle have been well characterized, its function and molecular mechanisms are not fully understood. Recent studies have revealed that Ki-67 plays important roles in localizing nucleolar material to the mitotic chromosome periphery and structuring perinucleolar heterochromatin, and it is also implicated in cancer development. However, its mechanisms of action remain unclear.
JOURNAL OF CELL SCIENCE
(2022)
Article
Oncology
Soon Bo Choi, Jung Min Park, Jee Hyun Ahn, Jieon Go, Jeeye Kim, Hyung Seok Park, Seung Il Kim, Byeong-Woo Park, Seho Park
Summary: This study aimed to explore the relationship between Ki-67 level and the prognosis of breast cancer patients, regardless of the timing of Ki-67 testing. The results showed that patients with higher Ki-67 levels had poorer survival, larger tumors, higher grade, and more aggressive treatment, regardless of when the testing was conducted.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
Article
Biology
Xi Yang, Ke Ma, Rui Chen, Naiyi Zhang, Yiting Meng, Jia Wen, Qinping Liao
Summary: This study aimed to evaluate various immunocytochemical biomarkers for cytodiagnosis of endometrial lesions. The results showed that different cut-off values for PTEN and Ki-67 could help differentiate endometrial cancer and precancerous lesions, improving diagnostic capabilities.
Article
Radiology, Nuclear Medicine & Medical Imaging
Yasemin Kayadibi, Burak Kocak, Nese Ucar, Yesim Namdar Akan, Pelin Akbas, Sibel Bektas
Summary: This study aimed to investigate the value of MRI-based radiomics in predicting Ki-67 expression of breast cancer. The results showed that the combination of ADC map-based selected radiomic features and a generalized linear model could be a promising non-invasive method to determine the Ki-67 expression level of breast cancer.
ACADEMIC RADIOLOGY
(2022)
Article
Pathology
Robert D. Morgan, George J. Burghel, Nicola Flaum, Michael Bulman, Philip Smith, Andrew R. Clamp, Jurjees Hasan, Claire Mitchell, Zena Salih, Emma R. Woodward, Fiona Lalloo, Joseph Shaw, Sudha Desai, Emma J. Crosbie, Richard J. Edmondson, Helene Schlecht, Andrew J. Wallace, Gordon C. Jayson, D. Gareth R. Evans
Summary: According to this study, some mutations in the tumor BRCA1/2 genes may be somatic mutations, and it may not be necessary to test all non-mucinous high-grade epithelial ovarian cancer cases for germline BRCA1/2 mutations.
JOURNAL OF CLINICAL PATHOLOGY
(2023)
Article
Oncology
Paul DiSilvestro, Susana Banerjee, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S. Sonke, Charlie Gourley, Amit Oza, Antonio Gonzalez-Martin, Carol Aghajanian, William Bradley, Cara Mathews, Joyce Liu, John McNamara, Elizabeth S. Lowe, Mei-Lin Ah-See, Kathleen N. Moore
Summary: Maintenance therapy with olaparib showed sustained progression-free survival benefit in newly diagnosed advanced ovarian cancer patients with a BRCA mutation. After a 7-year follow-up, there was a clinically meaningful improvement in overall survival. The incidence of myelodysplastic syndrome and acute myeloid leukemia was low.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Genetics & Heredity
Sue Philpott, Maria Raikou, Ranjit Manchanda, Michelle Lockley, Naveena Singh, Malcolm Scott, D. Gareth Evans, Julian Adlard, Munaza Ahmed, Richard Edmondson, Emma Roisin Woodward, Athena Lamnisos, Janos Balega, Angela F. Brady, Aarti Sharma, Louise Izatt, Anjana Kulkarni, Vishakha Tripathi, Joyce S. Solomons, Kevin Hayes, Helen Hanson, Katie Snape, Lucy Side, Steve Skates, Alistair McGuire, Adam N. Rosenthal
Summary: This study aimed to evaluate the effectiveness and cost-effectiveness of ovarian cancer surveillance in BRCA1/2-heterozygous women deferring risk-reducing surgery. The results showed that surveillance in a real-world setting was feasible and demonstrated similar performance to research trials, effectively down-staging ovarian cancer and saving costs.
JOURNAL OF MEDICAL GENETICS
(2023)
Article
Oncology
Britt W. Jensen, Julie Aarestrup, Kim Blond, Marit E. Jorgensen, Andrew G. Renehan, Dorte Vistisen, Jennifer L. Baker
Summary: Consistent childhood overweight or obesity may increase the rates of adult obesity-related cancer and decrease the rates of breast cancer. Adult-onset T2D confers additional risk for obesity-related cancer, but the effect does not differ across childhood BMI trajectories.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2023)
Article
Oncology
Robert D. D. Morgan, George J. J. Burghel, Nicola Flaum, Michael Bulman, Philip Smith, Andrew R. R. Clamp, Jurjees Hasan, Claire L. L. Mitchell, Zena Salih, Emma R. R. Woodward, Fiona Lalloo, Emma J. J. Crosbie, Richard J. J. Edmondson, Helene Schlecht, Gordon C. C. Jayson, D. Gareth R. Evans
Summary: Approximately 15% of patients diagnosed with high-grade non-mucinous epithelial ovarian cancer (EOC) have a germline BRCA1/2 mutation, with somatic mutations occurring more frequently in patients aged >= 80. Germline BRCA1/2 testing in this age group can be reserved for those with a detectable tumour BRCA1/2 mutation. Testing for tumour BRCA1/2 and homologous recombination deficiency is sufficient for patients aged >= 80 with non-mucinous high-grade EOC.
Review
Obstetrics & Gynecology
Denise R. Nebgen, Susan M. Domchek, Joanne Kotsopoulos, Joanne A. de Hullu, Emma J. Crosbie, Vincent Singh Paramanandam, Monique Brood van Zanten, Barbara M. Norquist, Theresa Guise, Serge Rozenberg, Allison W. Kurian, Holly J. Pederson, Nese Yuksel, Rachel Michaelson-Cohen, Sharon L. Bober, Agnaldo Lopes da Silva, Nora Johansen, F. Guidozzi, D. Gareth Evans, Usha Menon, Sheryl A. Kingsberg, C. Bethan Powell, Giovanni Grandi, Claudia Marchetti, Michelle Jacobson, Donal J. Brennan, Martha Hickey
Summary: Women with high inherited risk of ovarian cancer can undergo risk-reducing salpingo-oophorectomy (RRSO) between the ages of 35 and 45. While RRSO can save lives, it can also cause symptoms that negatively impact quality of life and long-term health. This scoping review explores the effects of RRSO on short- and long-term health and provides evidence-based international consensus recommendations for comprehensive care.
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY
(2023)
Article
Oncology
Thomas D. J. Walker, Zahra F. F. Faraahi, Marcus J. J. Price, Amy Hawarden, Caitlin A. A. Waddell, Bryn Russell, Dominique M. M. Jones, Aiste McCormick, N. Gavrielides, S. Tyagi, Laura C. C. Woodhouse, Bethany Whalley, Connor Roberts, Emma J. J. Crosbie, Richard J. J. Edmondson
Summary: Ovarian cancers are characterized by chromosomal instability. Impaired DNA damage response (DDR) is a major determinant of chemosensitivity. This study developed functional assays to monitor DDR and mitochondrial states and found that the comprehensive evaluation of DDR and mitochondrial status accurately predicts patient survival.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
T. Khassan, E. Smitten, N. Wood, C. Fotopoulou, J. Morrison, M. MacDonald, K. Baxter, R. J. Edmondson
Summary: This study investigated decision making for patients with advanced ovarian cancer and found significant variation in decision quality and participation between different centers. The results suggest that increasing discussion time and encouraging participation from all staff groups may increase the proportion of patients receiving optimal treatment regimens.
Article
Genetics & Heredity
Nicola Flaum, John Bowes, Miriam J. Smith, Emma J. Crosbie, Richard Edmondson, Artitaya Lophatananon, D. Gareth Evans
Summary: This study evaluated the association between BRCA1/2 heterozygotes and familial epithelial ovarian cancer (EOC) by constructing modified polygenic risk scores (PRS) validated by Barnes et al. It was found that combining PRS with age, family history, and hormonal factors significantly improved the discrimination ability of EOC risk, although the contribution of PRS was small. Larger prospective studies are needed to assess the usefulness of combined-PRS models in risk-reducing decisions.
GENETICS IN MEDICINE
(2023)
Article
Multidisciplinary Sciences
Amy Hawarden, Marcus Price, Bryn Russell, Godfrey Wilson, Laura Farrelly, Andrew Embleton-Thirsk, Mahesh Parmar, Richard Edmondson
Summary: For patients with advanced epithelial ovarian cancer, complete surgical cytoreduction is the most important factor affecting the outcome. However, it is difficult to predict which patients will benefit from this surgery, and few surgical outcome prediction tools have been validated. In this study, a promising three protein signature that was previously associated with suboptimal surgical debulking was externally validated, but the results showed poor predictive ability.
Article
Medical Informatics
Sarah Fremond, Sonali Andani, Jurriaan Barkey Wolf, Jouke Dijkstra, Sinead Melsbach, Jan J. Jobsen, Mariel Brinkhuis, Suzan Roothaan, Ina Jurgenliemk-Schulz, Ludy C. H. W. Lutgens, Remi A. Nout, Elzbieta M. van der Steen-Banasik, Stephanie M. de Boer, Melanie E. Powell, Naveena Singh, Linda R. Mileshkin, Helen J. Mackay, Alexandra Leary, Hans W. Nijman, Vincent T. H. B. M. Smit, Carien L. Creutzberg, Nanda Horeweg, Viktor H. Koelzer, Tjalling Bosse
Summary: This study developed an interpretable deep learning model for the molecular classification prediction of endometrial cancer based on histopathological slides, identifying morpho-molecular correlates and refining prognostication.
LANCET DIGITAL HEALTH
(2023)
Article
Oncology
Matthew E. J. Callister, Emma J. Crosbie, Philip A. J. Crosbie, Hilary A. Robbins
Summary: The advent of multi-cancer early detection (MCED) tests has the potential to revolutionize cancer diagnosis by improving patient outcomes through early diagnosis and curative therapies. The ongoing NHS-Galleri trial is evaluating an MCED test developed by GRAIL and using the incidence of late-stage cancer as its primary endpoint. However, we argue that this outcome may not always accurately reflect the expected effect of the test on cancer mortality due to micro-metastatic disease.
BRITISH JOURNAL OF CANCER
(2023)
Article
Pathology
Claire J. H. Kramer, Alba Llop-Guevara, Elisa Yaniz-Galende, Benedetta Pellegrino, Natalja T. ter Haar, Andrea Herencia-Ropero, Nicoletta Campanini, Antonino Musolino, Tjalling Bosse, Alexandra Leary, Violeta Serra, Maaike P. G. Vreeswijk
Summary: The RAD51 test shows promise as a biomarker for assessing functional homologous recombination deficiency (HRD). However, the robustness and reproducibility of the immunofluorescence-based RAD51 test in different academic laboratories have not been thoroughly investigated. This study tested the performance of the RAD51 assay in FFPE HGSOC samples and found that subtle differences in staining procedures resulted in low variability of RAD51 and γH2AX scores, but there was substantial variability in RAD51 scoring, likely due to technical and biological factors. Improving technical issues and identifying tissue quality requirements are essential to guide individual treatment for HGSOC patients.
JOURNAL OF PATHOLOGY CLINICAL RESEARCH
(2023)
Article
Primary Health Care
Sarah J. Kitson, Urwaa Khan, Emma J. Crosbie
Summary: This study investigated the attitudes towards personalised endometrial cancer risk assessments and the acceptability of potential prevention strategies among individuals and general practitioners. The results showed that the majority of respondents considered undergoing a risk assessment for endometrial cancer to be a good idea and were willing to participate. The common reasons for participation were to reduce risk, gain information, and potentially save lives. Additionally, GPs expressed willingness to offer endometrial cancer risk assessments if a tool was available.
Article
Obstetrics & Gynecology
Maya Whittaker, Jennifer C. Davies, Alexandra Sargent, Matt Sawyer, Emma J. Crosbie
Summary: This study aims to understand whether self-sampling can reduce carbon emissions in the NHS cervical screening program. By comparing the carbon footprint of routine cervical sampling, vaginal self-sampling, and first-void urine collection, the study found that routine sampling has a significantly higher carbon footprint compared to self-sampling approaches. There were negligible differences in the carbon footprint of different self-sampling methods. This highlights the importance of providing participants with information on the environmental impacts of screening options, enabling them to make informed choices.
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY
(2023)
Article
Pathology
Juliana Mota Siqueira, Yoshitsugu Mitani, Camilla Oliveira Hoff, Flavia Bonini, Luana Guimaraes de Sousa, Mario L. Marques-Piubelli, Anurag Purushothaman, Mutsumi Mitani, Hui Dai, Shiaw-Yih Lin, Michael T. Spiotto, Ehab Y. Hanna, Daniel J. McGrail, Adel K. El-Naggar, Renata Ferrarotto
Summary: B7-H4 expression pattern varies among different types of salivary gland carcinomas, and high B7-H4 expression is associated with poor prognosis in adenoid cystic carcinoma.
Article
Pathology
Basile Tessier-Cloutier, Felix K. F. Kommoss, David L. Kolin, Kristyna Nemejcova, Dupreez Smith, Jennifer Pors, Colin J. R. Stewart, W. Glenn Mccluggage, William D. Foulkes, Andreas von Deimling, Martin Kobel, Cheng-Han Lee
Summary: This study provides a detailed analysis of the clinical, pathological, immunohistochemical, and molecular features of DDOC/UDOC. The majority of patients presented with extraovarian disease and had rapid disease progression resulting in high mortality rate.
Review
Pathology
Sophia J. Wagner, Christian Matek, Sayedali Shetab Boushehri, Melanie Boxberg, Lorenz Lamm, Ario Sada, Dominik J. E. Winter, Carsten Marr, Tingying Peng
Summary: Computational pathology research driven by deep learning faces challenges in reproducibility and reusability. Codebase with good documentation and robustness and generalizability of models are crucial. The reuse of computational pathology algorithms is limited, and their application in clinical settings is even rarer. This study evaluates 160 peer-reviewed articles, providing criteria for data and code availability and statistical analysis of results.
Article
Pathology
Andres M. Acosta, Lynette M. Sholl, Fiona Maclean, Chia-Sui Kao, Thomas M. Ulbright
Summary: This study assessed the clinicopathologic and genomic features of 14 cases of testicular sex cord-stromal tumors. The results showed that CTNNB1 mutations are rare in these tumors, and most of them have genomic alterations similar to testicular sex cord-stromal tumors with pure or predominant spindle cell components.
Article
Pathology
Toru Odate, Kaishi Satomi, Takashi Kubo, Yuko Matsushita, Toshihide Ueno, Akira Kurose, Kohei Shomori, Tokiko Nakai, Reiko Watanabe, Keiko Segawa, Shusa Ohshika, Naritomo Miyake, Sayaka Kudo, Tatsunori Shimoi, Eisuke Kobayashi, Motokiyo Komiyama, Seiichi Yoshimoto, Fumihiko Nakatani, Akira Kawai, Yasushi Yatabe, Shinji Kohsaka, Koichi Ichimura, Hitoshi Ichikawa, Akihiko Yoshida
Summary: Inflammatory rhabdomyoblastic tumors (IRMTs) are newly recognized skeletal muscle tumors with uncertain malignant potential. This study investigated 13 IRMTs using clinicopathologic, genetic, and epigenetic methods. The results showed specific histologic features and genetic mutations in these tumors, and most of them exhibited benign behavior.
Article
Pathology
Dale L. Davis, Adam C. Lechner, David B. Chapel, Jonathan C. Slack, Chrystalle Katte Carreon, Bradley J. Quade, Carlos Parra-Herran
Summary: The Amsterdam Consensus Statement introduced the term maternal vascular malperfusion (MVM) to classify a group of findings related to impaired maternal-placental circulation. The study found that features such as low placental weight, accelerated villous maturation, decidual arteriopathy, and infarcts are associated with adverse obstetrical outcomes, while the role of other features like distal villous hypoplasia, excess multinucleated trophoblast, and retroplacental hemorrhage needs further research.
Review
Pathology
Alain C. Borczuk
Summary: COVID-19 is an acute respiratory illness that can progress to acute respiratory distress syndrome. While most patients recover completely, some may experience persistent respiratory dysfunction, known as long COVID. The pathogenesis involves immune and cellular disturbances.
Article
Pathology
Annikka Weissferdt, Cheuk H. Leung, Heather Lin, Boris Sepesi, William N. William, Stephen G. Swisher, Tina Cascone, J. Jack Lee, Abujiang Pataer
Summary: Neoadjuvant treatment of non-small cell lung cancer challenges traditional processing of pathology specimens, and accurate evaluation of residual tumor is crucial for assessing treatment efficacy.